pipeline

EXL01 in the Clinic

Evaluating the therapeutic potential of EXL01 in a diversified and complementary set of indications, in monotherapy or in combination

[Hover on the graphic to zoom]

Learn more about F. praustnizii in Inflammatory Bowel Diseases

EXL01 in Crohn's Disease

First-in-human Phase 1 maintenance trial (MAINTAIN) evaluating EXL01 for the maintenance of steroid-induced remission in patients with mild-to-moderate Crohn’s disease. Recruitment is completed.

A Phase 2 placebo-controlled randomized trial evaluating EXL01 for the postoperative maintenance in patients with Crohn’s disease. Planned in 2024.

EXL01 in Cancer Immunotherapy

Three Phase 2 immuno-oncology trials (BIG, EXLIBRIS & MOTHER, respectively in gastric cancer, non-small cell lung cancer & hepatocellular carcinoma) evaluating the potential of EXL01 in combination with cancer treatments, including Immune Checkpoint Inhibitors.

EXL01 in Infectious Diseases

Two part Phase 1/2 study, with a placebo-controlled randomized Phase 2 part, evaluating EXL01 in the prevention of recurrent C. difficile infection.
‍

EXL02

EXL02 is a pre-clinical Live Biotherapeutic candidate leveraging the properties of another gut bacteria, with a focus on its ability to activate the AhR-pathway.

EXL03

EXL03 is a preclinical recombinant protein candidate mimicking the properties of natural enzymes, in particular its ability to activate the Kynurenine pathway.

We would be glad to discuss partnership opportunities with you

Let's team up

Patients

READ

contact

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.